Becker's Healthcare February 19, 2024
Erica Carbajal

While a majority of corporate health insurance plans cover glucagon-like peptide-1 receptor agonist drugs for diabetes, less than a third said they cover the class of drugs for weight loss. However, experts say it’s only a matter of time before more employers move to cover obesity treatments, CNBC reported Feb. 16.

The report cited an October survey of 205 companies in which 76% of respondents said they offered GLP-1 coverage for diabetes, while just 27% said they provided coverage for weight loss. Meanwhile, 13% indicated they were considering extending coverage to include GLP-1s approved for obesity, including Wegovy and Zepbound.

Despite hesitancy stemming from the drugs’ high price tags and questions over long-term benefits costs, many experts still anticipate...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Employer, Patient / Consumer, Pharma, Pharma / Biotech
Women CEOs take a pay cut
How Gen Z will change the U.S. workforce
Will Artificial Intelligence (AI) Trigger Universal Health Care in America? What do expert Academics say?
Squabbling over the bill for weight-loss drugs
5 Strategies for Improving Mental Health at Work

Share This Article